BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/16/2016 10:47:00 AM | Browse: 353 | Download: 383
Publication Name World Journal of Hepatology
Manuscript ID 25600
Country of Manuscript Source United States
2016-03-16 08:46
Peer-Review Started
2016-03-18 10:58
To Make the First Decision
2016-04-15 08:21
Return for Revision
2016-04-19 16:19
2016-05-06 18:46
Second Decision
2016-06-27 17:05
Accepted by Journal Editor-in-Chief
2016-06-28 08:43
Accepted by Company Editor-in-Chief
2016-07-18 11:05
Articles in Press
2016-07-18 11:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-11-02 10:28
Publish the Manuscript Online
2016-11-16 10:47
ISSN 1948-5182 (online)
Open Access This article is an open-access article, which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Randomized Controlled Trial
Article Title Telbivudine <i>vs</i> tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study
Manuscript Source Unsolicited Manuscript
All Author List Zahari Krastev, Diana Petrova, Iskren Kotzev, Mustafa Kemal Celen, Meryl Mendelson, Richa Chandra, Priti Pandey and Kamal Hamed
Funding Agency and Grant Number
Funding Agency Grant Number
Novartis Pharma AG
Corresponding author Kamal Hamed, MD, MPH, Sr Worldwide Medical Director, Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ 07936, United States. kamal.hamed@novartis.com
Keywords Chronic hepatitis B; Glomerular filtration rate; Telbivudine; Tenofovir; Roadmap concept
Core Tip This was the first prospective, randomised, non-inferiority study in hepatitis B e antigen-negative chronic hepatitis B patients that compared telbivudine and tenofovir administered as per roadmap concept. Both treatments based on the roadmap approach were effective over a 156 wk treatment period. Non-inferiority of telbivudine arm to tenofovir arm was demonstrated at week 52, with over 91% of patients in each treatment arm achieving hepatitis B virus DNA level < 300 copies/mL. Both treaments showed acceptable safety profiles. Moreover, telbivudine showed an improvement in estimated glomerular filtration rate from baseline.
Publish Date 2016-11-16 10:47
Citation Krastev Z, Petrova D, Kotzev I, Celen MK, Mendelson M, Chandra R, Pandey P, Hamed K. Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study. World J Hepatol 2016; 8(32): 1402-1413
Url http://www.wjgnet.com/1948-5182/full/v8/i32/1402.htm
DOI http://dx.doi.org/10.4254/wjh.v8.i32.1402
Full Article (PDF) WJH-8-1402.pdf
Full Article (Word) WJH-8-1402.doc
Manuscript File 25600-Review.docx
Answering Reviewers 25600-Answering reviewers.pdf
Audio Core Tip 25600-Audio core tip.mp3
Clinical Trial Registration Statement DeclarationOf_HelsinkiConformation_Statement_20160316030312.pdf
Conflict-of-Interest Disclosure Form 25600-Conflict-of-interest statement.pdf
Copyright License Agreement 25600-Copyright assignment.pdf
Data Sharing Statement 25600-Data sharing statement.pdf
Signed Informed Consent Form(s) or Document(s) Informed_Consent_Statement_20160316025807.pdf
Institutional Review Board Approval Form or Document 25600-Institutional review board statement.pdf
Peer-review Report 25600-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 25600-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 25600-Scientific misconduct check.pdf
Scientific Editor Work List 25600-Scientific editor work list.pdf